Tower Research Capital LLC TRC Has $60,000 Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Tower Research Capital LLC TRC boosted its holdings in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 626.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,823 shares of the biopharmaceutical company’s stock after acquiring an additional 5,884 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Revance Therapeutics were worth $60,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Revance Therapeutics by 3.0% during the third quarter. Vanguard Group Inc. now owns 4,791,459 shares of the biopharmaceutical company’s stock valued at $54,958,000 after purchasing an additional 138,683 shares during the last quarter. Invesco Ltd. raised its stake in shares of Revance Therapeutics by 66.0% during the 3rd quarter. Invesco Ltd. now owns 2,902,440 shares of the biopharmaceutical company’s stock worth $33,291,000 after purchasing an additional 1,153,615 shares in the last quarter. Rubric Capital Management LP acquired a new stake in shares of Revance Therapeutics during the 3rd quarter valued at about $18,352,000. CIBC Asset Management Inc grew its stake in shares of Revance Therapeutics by 251.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,147,294 shares of the biopharmaceutical company’s stock valued at $10,085,000 after buying an additional 820,587 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in Revance Therapeutics by 3.6% in the third quarter. Wellington Management Group LLP now owns 1,082,420 shares of the biopharmaceutical company’s stock worth $12,415,000 after buying an additional 37,131 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Revance Therapeutics

In other Revance Therapeutics news, CFO Tobin Schilke sold 9,361 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $5.04, for a total value of $47,179.44. Following the completion of the transaction, the chief financial officer now owns 192,666 shares of the company’s stock, valued at approximately $971,036.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Revance Therapeutics news, insider Dwight Moxie sold 8,125 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $5.04, for a total transaction of $40,950.00. Following the completion of the transaction, the insider now owns 137,815 shares in the company, valued at $694,587.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Tobin Schilke sold 9,361 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $5.04, for a total value of $47,179.44. Following the completion of the transaction, the chief financial officer now directly owns 192,666 shares of the company’s stock, valued at $971,036.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,089 shares of company stock worth $143,642. Company insiders own 3.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on RVNC. Needham & Company LLC decreased their target price on shares of Revance Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. Barclays decreased their price objective on shares of Revance Therapeutics from $35.00 to $10.00 and set an “overweight” rating for the company in a report on Monday, January 29th. Mizuho lowered Revance Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $16.00 to $9.00 in a report on Monday, January 29th. Piper Sandler decreased their price target on Revance Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, February 29th. Finally, The Goldman Sachs Group raised their price objective on Revance Therapeutics from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Friday, March 1st. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.75.

Revance Therapeutics Trading Up 8.5 %

RVNC traded up $0.29 during midday trading on Monday, reaching $3.69. The company’s stock had a trading volume of 3,223,713 shares, compared to its average volume of 1,820,454. The company has a fifty day simple moving average of $4.95 and a 200 day simple moving average of $6.42. The stock has a market cap of $384.57 million, a P/E ratio of -0.97 and a beta of 1.06. Revance Therapeutics, Inc. has a twelve month low of $3.21 and a twelve month high of $37.98.

Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.17. The company had revenue of $69.80 million for the quarter, compared to the consensus estimate of $64.02 million. Sell-side analysts expect that Revance Therapeutics, Inc. will post -2.17 earnings per share for the current year.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.